社会ガイド
FDA Clinical Decision Support Software Guidance
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply.
このページでは3 分で読めます
概要
The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
ディープダイブ
Clinical decision support software provides information or recommendations to support healthcare decisions. FDA’s guidance explains how the agency assesses software functions under the applicable statutory criteria. Some functions may be excluded from the device definition when they meet specific conditions, including that a health professional can independently review the basis for recommendations. Other functions, including certain patient-specific analyses or device functions, may remain subject to oversight. The assessment is about what a particular software function does, its intended user, and how the output is used. A product can contain multiple functions with different regulatory status. A tool that presents evidence for a clinician to review is not automatically treated the same as software that directs diagnosis or treatment. FDA guidance also notes that functions intended for patients or caregivers may be assessed differently from clinician-facing support. Manufacturers should define each function and provide information that supports independent review where relevant. Clinicians should understand what inputs and evidence support a recommendation, the intended population, and limitations. A generated explanation is not itself proof of the underlying basis. Check current FDA guidance and product labeling for the specific function. This guide summarizes concepts and does not determine regulatory status for a product. Preserve examples of intended use and evidence that support the analysis, and revisit it when users, claims, or outputs change. Keep patient-facing and clinician-facing functions distinct in requirements and documentation.
戦略的影響
リスクと安全性
AI による壊滅的な被害も日常的な被害も、誰がリスクを理解し、誰が行動できるかにかかっています。
より明確な判決
国民と専門家のリテラシーは、強力な安全政策が政治的に可能かどうかを左右します。
誇大広告を打ち破る
明確な説明は、誇大広告、研究室の PR、曖昧な倫理劇場に囚われることを減らします。
The Future of FDA Clinical Decision Support Software Guidance
Decision-support products increasingly use machine learning and generative models, creating new questions about explainability and how clinicians review evidence. FDA guidance is updated as laws and technology change. Developers should monitor current agency materials and preserve a function-level analysis. Care teams need training to interpret outputs and should retain clinical judgment even when a tool is authorized. Developers should design interfaces that make the evidence and limitations easy to inspect, not merely generate a plausible explanation. Monitor outcomes and user feedback.
現実世界の実装
A clinician reviews sources and rationale behind a recommendation before acting.
A software team separates administrative reminders from patient-specific treatment recommendations.
A hospital confirms whether a function is intended for health professionals or patients.
A developer maps the product’s intended use to the criteria in current FDA guidance.
リスクとガードレール
能力が複雑になる一方で、実存的なリスクを SF として扱います。
高度な自律性の下での調整による表面製品の安全性を混乱させる。
英語以外や専門家ではない聴衆には、低品質の情報源しか提供されません。
実装ロードマップ
製品の危害、誤使用、制御不能/調整不良のリスクを分離します。
どのような証拠がタイムラインと重大度についてのあなたの見方を変えるかを尋ねてください。
マーケティング上の主張よりも、一次情報源と具体的な評価を優先します。
意識だけでなく、キャリア、政策、資金、スキルなど、行動経路を 1 つ特定します。
探検を続けましょう
Free newsletter
Get the daily AI briefing
Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Take the FDA Clinical Decision Support Software Guidance quiz
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
よくある質問
What is FDA Clinical Decision Support Software Guidance?
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply. The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
What does FDA evaluate in clinical decision-support software?
Regulatory analysis depends on the function and how it is used.
Why analyze a product function by function?
Regulatory assessment is not necessarily product-wide and uniform.
What should developers document for a function?
Function-specific documentation supports assessment and use.
What should clinicians do with a CDS recommendation?
CDS supports decisions and does not replace professional review.
学び続ける
関連ガイド
このトピックのために選ばれたその他のガイド